Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.8
(-1.54%)
TWD 28.8
(-1.54%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 280.8 Million TWD | -51.14% |
| 2022 | 574.67 Million TWD | 10.67% |
| 2021 | 519.27 Million TWD | -20.73% |
| 2020 | 655.05 Million TWD | 324.37% |
| 2019 | 154.36 Million TWD | 399.68% |
| 2018 | 30.89 Million TWD | -60.46% |
| 2017 | 78.13 Million TWD | -20.38% |
| 2016 | 98.13 Million TWD | -1.39% |
| 2015 | 99.51 Million TWD | 326.19% |
| 2014 | 23.35 Million TWD | -76.35% |
| 2013 | 98.73 Million TWD | -56.3% |
| 2012 | 225.91 Million TWD | 34.03% |
| 2011 | 168.55 Million TWD | -18.04% |
| 2010 | 205.65 Million TWD | -30.98% |
| 2009 | 297.95 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 14.33 Million TWD | -73.12% |
| 2024 Q2 | 23.44 Million TWD | 63.6% |
| 2023 Q1 | 227.94 Million TWD | 182.78% |
| 2023 Q4 | 53.3 Million TWD | 215.0% |
| 2023 Q2 | 52.52 Million TWD | -76.96% |
| 2023 FY | 280.8 Million TWD | -51.14% |
| 2023 Q3 | 16.92 Million TWD | -67.78% |
| 2022 Q1 | 150.56 Million TWD | 48.18% |
| 2022 Q4 | 80.6 Million TWD | -44.45% |
| 2022 Q3 | 145.1 Million TWD | -26.86% |
| 2022 FY | 574.67 Million TWD | 10.67% |
| 2022 Q2 | 198.39 Million TWD | 31.77% |
| 2021 Q2 | 149.35 Million TWD | 36.31% |
| 2021 Q3 | 102.47 Million TWD | -31.39% |
| 2021 FY | 519.27 Million TWD | -20.73% |
| 2021 Q1 | 109.56 Million TWD | -10.84% |
| 2021 Q4 | 101.6 Million TWD | -0.84% |
| 2020 Q4 | 122.88 Million TWD | 295.12% |
| 2020 Q3 | 31.1 Million TWD | -64.43% |
| 2020 Q1 | 27.5 Million TWD | -38.02% |
| 2020 FY | 655.05 Million TWD | 324.37% |
| 2020 Q2 | 87.43 Million TWD | 217.85% |
| 2019 Q4 | 44.37 Million TWD | 86.82% |
| 2019 FY | 154.36 Million TWD | 399.68% |
| 2019 Q3 | 23.75 Million TWD | 106.48% |
| 2019 Q2 | 11.5 Million TWD | -72.26% |
| 2019 Q1 | 41.47 Million TWD | 393.13% |
| 2018 FY | 30.89 Million TWD | -60.46% |
| 2018 Q3 | -1.54 Million TWD | -108.74% |
| 2018 Q2 | 17.71 Million TWD | 180.46% |
| 2018 Q1 | 6.31 Million TWD | -72.39% |
| 2018 Q4 | 8.41 Million TWD | 643.28% |
| 2017 Q1 | 753 Thousand TWD | -97.71% |
| 2017 Q3 | 67.6 Million TWD | 616.31% |
| 2017 Q2 | -13.09 Million TWD | -1838.78% |
| 2017 Q4 | 22.87 Million TWD | -66.16% |
| 2017 FY | 78.13 Million TWD | -20.38% |
| 2016 Q4 | 32.87 Million TWD | 48.52% |
| 2016 Q1 | 23.93 Million TWD | -73.39% |
| 2016 Q3 | 22.13 Million TWD | 15.37% |
| 2016 FY | 98.13 Million TWD | -1.39% |
| 2016 Q2 | 19.18 Million TWD | -19.82% |
| 2015 Q3 | 21.56 Million TWD | 25.12% |
| 2015 FY | 99.51 Million TWD | 326.19% |
| 2015 Q1 | -29.2 Million TWD | -239.49% |
| 2015 Q2 | 17.23 Million TWD | 159.01% |
| 2015 Q4 | 89.92 Million TWD | 316.98% |
| 2014 Q2 | 27.58 Million TWD | 160.56% |
| 2014 Q3 | -35.75 Million TWD | -229.63% |
| 2014 Q1 | 10.58 Million TWD | 2628.09% |
| 2014 FY | 23.35 Million TWD | -76.35% |
| 2014 Q4 | 20.93 Million TWD | 158.56% |
| 2013 Q1 | 41.77 Million TWD | 48.92% |
| 2013 FY | 98.73 Million TWD | -56.3% |
| 2013 Q3 | 11.39 Million TWD | -74.79% |
| 2013 Q4 | 388 Thousand TWD | -96.59% |
| 2013 Q2 | 45.18 Million TWD | 8.16% |
| 2012 Q2 | 96.22 Million TWD | 109.92% |
| 2012 FY | 225.91 Million TWD | 34.03% |
| 2012 Q4 | 28.05 Million TWD | -49.07% |
| 2012 Q3 | 55.07 Million TWD | -42.76% |
| 2012 Q1 | 45.84 Million TWD | -21.5% |
| 2011 Q2 | 35.5 Million TWD | -13.91% |
| 2011 Q1 | 41.23 Million TWD | 6.63% |
| 2011 Q3 | 33.41 Million TWD | -5.89% |
| 2011 FY | 168.55 Million TWD | -18.04% |
| 2011 Q4 | 58.39 Million TWD | 74.78% |
| 2010 Q1 | 40.14 Million TWD | 0.0% |
| 2010 FY | 205.65 Million TWD | -30.98% |
| 2010 Q2 | 60.26 Million TWD | 50.12% |
| 2010 Q4 | 38.67 Million TWD | -41.9% |
| 2010 Q3 | 66.56 Million TWD | 10.46% |
| 2009 FY | 297.95 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 141.71 Million TWD | -98.149% |
| Sinphar Pharmaceutical Co.,Ltd. | 286.05 Million TWD | 1.834% |
| Panion & Bf Biotech Inc. | 156.82 Million TWD | -79.054% |
| GenMont Biotech Incorporation | 6.98 Million TWD | -3918.446% |
| Abnova (Taiwan) Corporation | 47.19 Million TWD | -495.01% |
| Adimmune Corporation | -722.74 Million TWD | 138.853% |
| Tanvex BioPharma, Inc. | -2.1 Billion TWD | 113.367% |
| Polaris Group | -1.84 Billion TWD | 115.203% |
| Energenesis Biomedical CO.,LTD. | -261.83 Million TWD | 207.246% |
| UnicoCell Biomed Co., Ltd. | -96.28 Million TWD | 391.659% |
| PELL Bio-Med Technology Co. Ltd. | -411.24 Million TWD | 168.282% |